Organ-on-a-Chip Companies & Market: How to Choose a Supplier

What Is an Organ-on-a-Chip Company?

An organ-on-a-chip company supplies hardware, consumables or services used to culture human cells under controlled perfusion in microfluidic devices that reproduce organ-level function. The term covers instrument manufacturers, chip fabricators, flow control specialists and contract research organisations — not a single business model.

The label is broad because the technology is modular. A functioning organ-on-a-chip experiment requires a chip with the right channel geometry and membrane, a cell source, a means of driving flow at physiologically relevant shear stress, an incubation environment, and a readout. Few suppliers cover all five. Most laboratories therefore assemble a system from two or three vendors rather than buying a turnkey platform, which makes interoperability a purchasing criterion in its own right rather than an afterthought.

Types of Organ-on-a-Chip Provider

The supplier landscape divides into four capability segments: full-platform vendors, chip and consumable specialists, flow control and perfusion specialists, and contract research organisations. Each solves a different problem, and the right choice follows from what a laboratory already owns and how much protocol control it needs to retain.

Figure 1. Capability coverage by provider type across the organ-on-a-chip system stack. Most laboratories buy across two or more columns.

Full-platform vendors

Full-platform vendors sell an integrated instrument: chips, fluid handling, environmental control and often software, validated together as one product. The appeal is a short path to first results and a single support contact.

The trade-off is protocol flexibility. Integrated platforms are typically optimized for a defined set of models, and adapting them to a chip geometry or flow regime the vendor did not anticipate can be difficult or impossible. This suits laboratories running established assays at volume; it suits method development less well.

Chip and consumable specialists

Chip specialists fabricate the microfluidic devices themselves — glass, thermoplastic (COC, PMMA) or PDMS — including membrane-separated dual-channel designs for barrier tissues and geometries for gradient generation or organoid trapping. They usually supply the chip alone, leaving perfusion to the customer.

Chips from these suppliers are often the most physiologically specialized on the market, and consumable cost per experiment is the dominant line item in a long-running study. Verify material compatibility early: PDMS absorbs small hydrophobic molecules, which matters for pharmacokinetic work.

Flow control and perfusion specialists

Flow control specialists supply the instrumentation that drives and measures fluid movement through a chip: pressure controllers, flow sensors, valves and recirculation modules. They are chip-agnostic by design, which makes them the layer laboratories most often add to an existing setup.

This is the segment where reproducibility is decided. Pressure-driven flow reaches a stable setpoint in well under a second and delivers pulseless flow, whereas syringe and peristaltic pumps introduce mechanical pulsation that propagates into the culture as shear stress variation. Fluigent’s Flow EZ pressure controller is used in this role.

CROs and service providers

Contract research organizations run organ-on-a-chip studies on a laboratory’s behalf and return data rather than hardware. This removes capital expenditure and the months of method development that a new platform requires.

Services account for a substantial share of market revenue — one 2025 analysis put the services segment above half of total value. The limitation is strategic: outsourcing builds no internal capability, and per-study costs accumulate quickly for programmes that run continuously rather than once.

Organ-on-a-Chip Market Size and Growth

Published estimates of the organ-on-a-chip market cluster between USD$ 150 million and USD$ 230 million for 2025, with compound annual growth rates forecast between 21% and 36%. The spread is wide because analysts define the market boundary differently — some count consumables and services, others devices alone.

Three widely cited 2025–2026 estimates illustrate the range. Grand View Research sizes the market at USD$ 186.1 million in 2025, reaching USD$ 1,210.0 million by 2033 at a 26.4% CAGR. Fortune Business Insights gives USD$ 210.43 million for 2025 and USD$ 1,993.10 million by 2034 at 27.58%. Precedence Research reports USD$ 227.40 million in 2025 and USD$ 4,191.15 million by 2035 at 33.83%.

Figure 2. Three published 2025 market estimates and their forecast growth rates. Forecast horizons differ, which accounts for part of the CAGR spread.

A caution for anyone citing these figures: syndicated press releases occasionally reproduce these numbers with the wrong unit, turning millions into billions. Headline market sizes in the hundreds of billions of dollars for organ-on-a-chip do not survive comparison with the sector’s actual revenue base and should be checked against the originating report before use.

Market Segmentation by Application and End User

The market segments by application, by organ model and by end user. Drug discovery dominates every published breakdown, pharmaceutical and biotechnology companies dominate the buyer side, and liver models lead among individual organ types.

Drug discovery and preclinical testing

Drug discovery is the largest application segment, reported at 62.7% of 2025 revenue by one analysis and 45% by another — the difference reflecting whether toxicology is counted separately. The commercial driver is attrition: compounds that pass animal testing still fail in human trials, and human-relevant models are positioned to catch those failures earlier. Our review of organ-on-chip in drug development covers this in detail.

Toxicology and safety assessment

Toxicology is the application closest to regulatory acceptance, because safety endpoints are better defined than efficacy endpoints and easier to qualify against a specified context of use. Liver-on-a-chip leads organ-type revenue at roughly a third of the 2025 market, reflecting the centrality of hepatotoxicity and drug metabolism to preclinical safety packages.

Disease modelling and personalized medicine

Disease modelling and personalized medicine are the fastest-growing application segments, driven by patient-derived iPSC lines that allow a chip to be populated with a specific individual’s cells. Multi-organ and body-on-a-chip configurations grow fastest among device types, since systemic effects and metabolite-mediated toxicity cannot be observed in single-organ models.

Regional Organ-on-a-Chip Markets

North America holds the largest regional share of the organ-on-a-chip market, estimated between 42% and 52% for 2025 depending on the source. Asia-Pacific is consistently identified as the fastest-growing region, with forecast CAGRs near 29%.

North America

The United States accounts for most North American revenue and hosts the densest concentration of platform developers, largely through academic spin-outs. Federal agencies including the NIH, FDA and DARPA have funded organ-on-a-chip development for over a decade, and regulatory momentum since 2025 has made the US the primary market where non-animal data has an explicit path into a submission.

Europe (UK, France, Germany)

Europe is the second-largest region and the center of standardization work. The European Organ-on-Chip Society (EUROoCS), founded in 2018, and the CEN-CENELEC Focus Group on Organ-on-Chip published an international standardization roadmap in July 2024 after two years of work by 120 experts — a first step toward ISO standards, now progressing through ISO/TC 276/SC 2.

In the UK, the NC3Rs had committed £28.6 million to research using microphysiological systems as of March 2023. France, Germany and the Netherlands host substantial academic programs; Fluigent is headquartered in France and supplies laboratories across the world.

Japan and South Korea

Japan runs the most structured national program outside Europe. The Japan Agency for Medical Research and Development launched AMED-MPS in 2017 with an annual budget reported at JPY 500 million, developing liver, gut, kidney and blood-brain barrier models alongside device manufacturing and standardization workstreams. Successor projects MPS2 and MPS-RS focus on industrial implementation and regulatory integration.

South Korea’s activity is concentrated in government research institutes and pharmaceutical partnerships rather than a single national program.

China

China is expanding rapidly in both research output and domestic manufacturing. The Chinese Society of Biotechnology released the country’s first group standard for human intestine-on-a-chip in April 2024, specifying terminology, technical requirements, detection methods and quality control — an indication that standardization is being pursued nationally as well as through international bodies.

South America

South America is at an earlier stage, with activity centered on Brazil. National initiatives including RENAMA and BraCVAM, a partnership between Anvisa and INCQS/Fiocruz, coordinate work on alternatives to animal testing, and a Human-on-a-Chip project began at the National Laboratory of Biosciences in 2015. Regional demand is currently served largely by imported instrumentation.

Trends Driving the Organ-on-a-Chip Industry

Four trends shape the industry: regulatory acceptance of non-animal methods, standardization, automation for throughput, and the shift from single-organ to multi-organ systems. Together they are moving organ-on-a-chip from a specialist research technique toward routine preclinical use.

Standardization is the least visible and arguably most consequential. Without agreed definitions of chip design, cell sourcing and functional validation, results are difficult to transfer between laboratories — the barrier that has kept the technology out of routine regulatory submissions. The CEN-CENELEC roadmap and the ISO sub-committee address this directly.

Automation is the commercial trend. Manual perfusion limits an operator to a handful of chips, which caps statistical power and rules out screening applications. Automated platforms that manage flow, media exchange and sampling across parallel chips convert the technology from a demonstration into an assay, and this is where most platform development investment now goes.

Regulatory Drivers: From Animal Testing to Human-Relevant Models

Regulatory change is the strongest single driver of market growth. On 10 April 2025 the FDA announced a plan to phase out the animal testing requirement for monoclonal antibodies and other drugs, publishing a roadmap that names organ-on-a-chip systems among the New Approach Methodologies (NAMs) intended to replace them.

organ on chip market milestones timeline from FDA

Figure 3. Regulatory and standardisation milestones, 2015–2026. Sourced from FDA, CEN-CENELEC, EUROoCS, AMED and national standards bodies.

The roadmap builds on the FDA Modernization Act 2.0, which permitted the agency to accept non-animal data. The stated goal is for animal studies to become the exception rather than the norm within three to five years. In April 2026 the FDA published a one-year progress report, and a March 2026 draft guidance set out four validation principles — context of use, human biological relevance, technical characterization, and fit-for-purpose.

For buyers, the practical consequence is that documentation matters as much as biology. A platform whose performance is characterized, reproducible and publishable is positioned for regulatory use; one that produces results without traceable flow conditions is not.

How to Choose an Organ-on-a-Chip Supplier

Choose a supplier on five criteria: throughput requirements, chip compatibility, flow control precision, published validation, and total cost of ownership. Brands are not directly comparable because suppliers offer different products and chips, the choice of a brand depends on the application.

Criterion	What to ask	Why it matters	How to verify
Throughput and automation	How many chips run in parallel, unattended, for how long?	Determines whether the system supports screening or only single experiments	Request a run log or protocol from an existing user
Chip compatibility	Does the instrument work with third-party chips and standard fittings?	Closed systems lock consumable supply and block custom geometries	Check connector standards and published chip compatibility lists
Flow control precision	What is the settling time, flow stability and pulsation amplitude?	Shear stress variation alters cell phenotype and confounds results	Request specifications with units, not qualitative claims
Published validation	Which peer-reviewed papers used this exact configuration?	Distinguishes a validated method from a marketing claim	Search the literature for the instrument, not the vendor
Total cost of ownership	What is the per-experiment consumable cost over three years?	Consumables usually exceed instrument cost over a platform’s life	Model chips, reagents, service and training together

Throughput and automation requirements

Establish the required number of parallel conditions before evaluating any instrument. A mechanism study needs a handful of chips; a compound screen needs dozens with automated media exchange. Buying a platform sized for the wrong regime is the most expensive common error, and it is not recoverable by adding modules later.

Chip compatibility and open vs closed systems

Closed systems accept only the vendor’s chips. That guarantees compatibility and fixes consumable supply and pricing for the platform’s lifetime. Open systems accept third-party chips and custom geometries, which matters if a model requires a specific membrane, coating or channel dimension. Establish which regime a supplier operates before committing, because migration later means replacing the instrument.

Flow control precision and reproducibility

Ask for flow specifications in units. Relevant figures are settling time to a stable setpoint, flow stability under changing hydraulic resistance, and pulsation amplitude. Pressure-driven systems with feedback flow sensors deliver pulseless flow and respond in milliseconds; displacement pumps do not. Since shear stress is a differentiating stimulus in endothelial and epithelial models, pulsation is an experimental variable, not a specification detail.

Published validation and technical support

Search for the instrument in the peer-reviewed literature rather than relying on a vendor’s case studies, and look for papers from groups other than the manufacturer’s collaborators. A university tissue chip platform case study illustrates the kind of third-party evidence worth seeking. Assess support separately: response time and applications expertise determine how long first results take.

Total cost of ownership

Model three years, not the purchase order. Include chips at the intended experimental rate, reagents and cells, service contracts, and staff time for method development. Consumable spend routinely exceeds instrument cost over a platform’s life, which is why a cheaper instrument tied to expensive proprietary chips is frequently the costlier option. Detailed pricing and configuration are best handled through a quotation.

Where Fluigent Fits

Fluigent supplies the flow control and perfusion layer, and complete organ-on-a-chip platforms built on it. The Omi automated organ-on-chip platform provides recirculating perfusion and automated media handling for parallel chip culture, while pressure-based instruments serve laboratories building around chips they have already selected.

That positioning follows from the modular reality described above. Because Fluigent instruments are chip-agnostic, they integrate with third-party devices and custom geometries rather than requiring a laboratory to standardise on one consumable supply. The cell perfusion application package bundles the components for controlled perfusion culture, and the cell culture and organ-on-a-chip application hub sets out the supported configurations. Ongoing developments are published in the organ-on-chip news section.

Frequently Asked Questions

How big is the organ-on-a-chip market?

Published estimates place the 2025 organ-on-a-chip market between roughly USD 150 million and USD 230 million, with forecast CAGRs from 21% to 36%. Estimates diverge because analysts draw the boundary differently around consumables and services. Check the originating report rather than a press release.

What types of organ-on-a-chip company are there?

Four capability segments: full-platform vendors selling integrated instruments; chip and consumable specialists fabricating microfluidic devices; flow control and perfusion specialists supplying pressure controllers, sensors and recirculation hardware; and contract research organisations running studies as a service.

How do I choose an organ-on-a-chip supplier?

Evaluate five criteria: required throughput and automation level, chip compatibility including open versus closed architecture, flow control precision expressed in units, independent published validation of the exact configuration, and three-year total cost of ownership including consumables.

What are the main trends shaping the organ-on-a-chip market?

Regulatory acceptance of non-animal methods, notably the FDA’s 2025 roadmap on New Approach Methodologies; international standardisation through CEN-CENELEC and ISO/TC 276/SC 2; automation enabling parallel chip culture; and the move from single-organ to multi-organ systems.

Related Expertises

References

1. U.S. Food and Drug Administration. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. Press announcement, 10 April 2025. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs

2. U.S. Food and Drug Administration. New Approach Methodologies (NAMs). Science and Research Special Topics. https://www.fda.gov/science-research/science-and-research-special-topics/new-approach-methodologies-nams

3. U.S. Food and Drug Administration. Roadmap to Reducing Animal Testing in Preclinical Safety Studies. April 2025. https://www.fda.gov/files/newsroom/published/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf

4. CEN-CENELEC. The Organ-on-Chip Roadmap has been published. 10 July 2024. https://www.cencenelec.eu/news-events/news/2024/brief-news/2024-07-10-organ-on-chip/

5. European Organ-on-Chip Society (EUROoCS). Launch international Organ-on-Chip Standardization Roadmap at EUROoCS 2024. https://euroocs.eu/launch-international-organ-on-chip-standardization-roadmap-at-euroocs-2024/

6. Ishida, S. Research and development of microphysiological systems in Japan supported by the AMED-MPS project. Frontiers in Toxicology, 3:657765 (2021). https://pubmed.ncbi.nlm.nih.gov/35295097/

7. NC3Rs. Microphysiological systems. 3Rs resource library. https://nc3rs.org.uk/3rs-resource-library/microphysiological-systems

8. Grand View Research. Organ-on-a-Chip Market Size & Share Report, 2026–2033. https://www.grandviewresearch.com/industry-analysis/organ-on-a-chip-market-report

9. Fortune Business Insights. Organs On Chips Market Size, Share. https://www.fortunebusinessinsights.com/organs-on-chips-market-114512

10. Precedence Research. Organ-on-a-Chip Market Size, Share and Trends 2026 to 2035. https://www.precedenceresearch.com/organ-on-a-chip-market

Organ-on-a-Chip Companies: Market Overview and How to Choose a Supplier